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Objective: To investigate the inherited mutations and their association with clinical
features and treatment response in young-onset prostate cancer patients.
Method: Targeted gene sequencing on 139 tumor susceptibility genes was conducted
with a total of 24 patients diagnosed with PCa under the age of 63 years old. Meanwhile,
the related clinical information of those patients is collected and analyzed.
Results: Sixty-two germline mutations in 45 genes were veriﬁed in 22 patients. BRCA2
(20.8%) and GJB2 (20.8%) were found to be the most frequently mutated, followed by
CHEK2, BRCA1, PALB2, CDKN2A, HOXB13, PPM1D, and RECQL (8.3% of each, 2/24).
Of note, 58.3% (14/24) patients carry germline mutations in DNA repair genes (DRGs).
Four families with HRR (homologous recombination repair)-related gene mutations were
described and analyzed in detail. Two patients with BRCA2 mutation responded well to
the combined treatment of androgen deprivation therapy (ADT) and radiotherapy/
chemotherapy.
Conclusion: Mutations in DRGs are more prevalent in early-onset PCa with advanced
clinical stages, and these patients had shorter progression-free survival. ADT Combined
with either radiotherapy or chemotherapy may be effective in treating PCa caused by
HRR-related gene mutations.
Keywords: prostate cancer, early-onset, next-generation sequencing, germline mutations, homologous
recombination associated genes

INTRODUCTION
Prostate cancer (PCa) is the second most common cancer in men worldwide (1). More recent data
indicate that genetic mutations predispose the patients to PCa (2, 3), evidenced by more than 60 loci
linked to approximately 30% of familial PCa (4). It has been estimated that about 42% PCa risks,
especially for the early-onset PCa, are attributable to genetic alterations (5). Mutations in DRGs
especially HRR-related genes such as BRCA1 and BRCA2 are the well-established risk factors for
PCa (6), with approximately 10% PCa patients harboring deleterious mutations in DRGs (7).
Furthermore, compared with those carrying somatic mutations in DRGs, patients with hereditary
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prostate cancer was made during follow-up based on the
American AUA guidelines (2018 edition): (1) Serum
testosterone <50ng/dL (<1.7nmol/L); (2) Elevated PSA: a PSA
increase of >2ng/ml from the lowest level at a minimum of 3
weeks interval or an increase of 25% from the lowest level at the
second measurement. Two or more new lesions detected in a
bone scan are indicative of disease progression as well.

germline mutations have an earlier onset, a higher propensity to
metastasis, and shorter progression-free survival (8).
HRR is the most efﬁcient repair tool for DNA double-strand
breaks (DSB) with high ﬁdelity (9). BRCA1/2, together with their
functional-related factors such as ATM, ATR, and PALB2, form
HRR complexes and play pivotal roles in maintaining genome
stability (9). Cells with mutations in any of these genes are more
vulnerable to DNA damage and cancer development, especially
when they are exposed to either endogenous or exogenous
attacks (10, 11). Therefore, mutations in HRR-related genes
have been frequently observed in different cancer types,
including breast, ovarian, pancreatic, stomach, laryngeal, and
PCa (12). The BRCA1/2 mutations are predominantly observed
in breast and ovarian cancer in women (13) and PCa in men
(14). Germline BRCA1/2 mutations are also associated with
higher Gleason scores (≥8), a more aggressive phenotype with
a higher probability of nodal involvement, distant metastasis,
and shorter overall survival (15, 16). Germline BRCA2 and
BRCA1 mutations present in 1.2% and 0.44% PCa (17),
respectively. The frequency of BRCA2 mutation in early-onset
PCa patients (<65 years old) could be as high as 2.2% (18). Based
on these data, we hypothesized that germline mutations could be
one of the important underlying mechanisms for PCa early
onset. To test this hypothesis, we investigated the frequency of
genetic mutations of 139 tumor-susceptibility genes in 24 youngonset PCa patients. We found that mutations in DRGs are not
only more prevalent in early-onset PCa, patients with these
mutations also have much shorter progression-free survivals.

Sample Collection and gDNA Library
Peripheral blood was collected from the elbow vein into EDTAcontaining tubes and stored at 4°C for further examination. Total
DNA is extracted from the mononuclear cells. AllPrep DNA/
RNA Mini Kit (Qiagen 80204) was used for gDNA extraction.
The size, quality, and quantity of the puriﬁed gDNA were
estimated using the 2200 Bioanalyzer (Agilent Technologies).
The gDNA library was constructed using a KAPA Hyper Prep kit
according to the manufacturer’s protocols (Kapa Biosystems).
The quantities of the library were estimated using Qubit 3
(Thermo Fisher).

Panel Design and Targeted Sequencing
A panel of 139 genes was used in our research (supplementary
ﬁle), and the gDNA library was enriched for regions of this
custom-designed probe manufactured by Agilent. The panel is
designed according to the genes that have been reported to
be associated with hereditary tumors based on NCCN (National
Comprehensive Cancer Network) guideline, HGMD (The
Human Gene Mutation Database) and TCGA (The Cancer
Genome Atlas) database, as well as previously reported inherit
susceptibility genes. About 750ng of library DNA was hybridized
with two hybridization reagents and blocking agents of
the SureSelectXT Target Enrichment System (Agilent
Technologies). The enriched libraries were ampliﬁed with the
P5/P7 primer. After being qualiﬁed by the 2200 Bioanalyzer,
Qubit3, and a qPCR NGS library quantiﬁcation kit (Agilent
Technologies), the libraries were sequenced on a Hiseq X10
platform (Illumina, San Diego, CA). 18 DRGs (ATM, ATR,
BRCA1, BRCA2, BRIP1, CHEK2, FAM175A, FANCA, GEN1,
MLH1, MRE11, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C,
RAD51D) are grouped (1).

PATIENTS AND METHODS
Patients
Initially, 239 PCa patients admitted to Daping hospital between
September 2016 and December 2020 were screened for this study
with the protocol approved by the ethics committee of the Third
Afﬁliated Hospital of the PLA Army Medical University (ethics
number: 2018 No. 28). The following criteria were used
for inclusion:
1) Patients that had been pathologically diagnosed with prostate
cancer
2) Age at diagnosis is younger than 65
3) Informed consent: volunteered to participate in this study
Most individuals were excluded due to the following criteria:
1) Limited sample availability or unqualiﬁed samples
2) Unwillingness to participate in this study
3) Unavailability of following-up data

Bioinformatics Analysis
Primary processing of NGS data for blood samples was
performed using Trimmomatic (0.36), including
demultiplexing and masking of dual-index adapter sequences.
Sequences were aligned against the human reference genome
(GRCh37/hg19) using BWA (version 0.7.10). IGV was used to
ﬁlter alignment and sequence artifacts. Point mutations, small
insertions, and deletions were identiﬁed by Samtools (version
1.3.1) and Spindel (version 0.2.5b8, 20151210). A mutation was
ﬁlltered if the depth was smaller than 5, the mutational frequency
was less than 20%, or was recurrently found in healthy
individuals according to multiple database including NHLBI
(National Heart Lung and Blood Institute) Exome Sequencing
Project, 1000 Genomes Project, Exome Aggregation Consortium
and gnomAD. The effects of variants were annotated using
Oncotator (https://software.broadinstitute.org/cancer/cga/

A total of 24 PCa patients were included in the study with
their clinical data, including ages, PSA levels at diagnosis, biopsy
Gleason score, pathological types from needle biopsy and
surgical specimens, metastasis status, clinical stages, androgen
deprivation therapy (ADT) strategies, and gene sequencing
results. Additionally, the levels of testosterone and PSA during
ADT were monitored. The diagnosis of castration-resistant
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oncotator) and Variant Effect Predictor (https://grch37.ensembl.
org/info/docs/tools/vep/index.html), as well as an in-house
database (GenentronDB). The pathogenicity of germline
mutations was analyzed according to the ACMG Guidelines
(2015 edition), only mutations that are pathogenic/likely
pathogenic and VUS (variant of uncertain signiﬁcance) are
investigated. All the raw data of genetic sequencing have been
deposited in public GSA database (https://ngdc.cncb.ac.cn/gsahuman/, accession number: HRA001716).

all samples accounted for 82.3% (51/62). 16.1% (10/62) of the
patients have either frameshift (3 frameshifts in FANCD2,
BRCA2, and PALB2 gene), non-frameshift (2 non-frameshift in
TGFBR1 and APC genes), or stop-gained mutations (5 stopgained mutations in BRCA2, CDKN2A, and VEGFA genes),
which potentially affect the functions of the encoded proteins.
Interestingly, we found that fourteen patients (14/24, 58.3%)
have one or more germline mutations in above-mentioned 18
DRGs. The most frequently mutant genes were BRCA2 (5/24)
and GJB2 (5/24), followed by CDKN2A, CHEK2, EGFR,
HOXB13, PPM1D, and RECQL (2/24). Mutation sites of the
main genes are listed below (Figure 2).

Statistical Analyses
SPSS 22.0 (IBM, USA) was used for statistical analysis. Mean age
at diagnosis, TNM staging, Gleason score, and PSA level were
used as classiﬁcation criteria. The t-test was used for continuous
variables, and the chi-square test or Fisher exact test was used for
classiﬁcation variables. For data that did not ﬁt a normal
distribution, nonparametric statistical tests were used. P < 0.05
was considered statistically signiﬁcant.

Clinical Feature
Compared to those with non-DRGs mutation carriers, the 14
patients with DRGs’ mutations have a tendency of higher overall
Gleason score, higher PSA level at diagnosis, and younger ages
(54 years vs 55.9 years, P=0.36). 64% (9/14 patients) of the
patients with DRGs’ mutations have a Gleason score of 8 or
higher compared to 40% (4/10 patients, P =0.41) of the noncarriers. The average PSA level of the DRGs mutation carriers is
120ng/mL compared to that 41.2 ng/mL (P =0.15) of the nonDRGs mutation carriers. In addition, at the time of diagnosis,
50% (7/14 patients) of patients with DRGs’ mutations have their
tumor staged at T3/T4 comparing to 30% (3/10 patients, P=0.42)
of the non-DRGs mutation carriers with a similar staging. Of the
ﬁve patients with GJB2 mutations, two patients (one of them has
homozygous GJB2 mutation) were at the T4 stage at their
diagnosis with a Gleason score of 9; 1 patient at stage T3
(Gleason score of 9); 2 patients at stage T2 (Gleason score of 7
and 8, respectively). In addition, four of the ﬁve patients have a
high level of PSA (>100ng/mL). Three CHEK2 mutations were
detected in 2 patients at stage T2 and T3, respectively, at
their diagnoses.

Pedigree Analysis
Six of the 14 patients with germline mutations in DRGs were
assembled to further investigate genetic characters in their
pedigrees. Four patients and their families agreed to participate
in the continued study. Peripheral blood was drawn from the
elbow vein of the ﬁrst/second-degree relatives of these four
patients; then Sanger sequencing was conducted to evaluate the
hereditary feature.

RESULTS
Patients
Twenty-four patients were diagnosed with PCa by prostate
needle biopsy or surgical specimens. Among these patients,
eight and four have ﬁrst-degree and none-ﬁrst-degree relatives
with a history of cancer, respectively. The remaining patients
have no family history of cancer. At diagnosis, the average age is
54.8 (47~62 years old), and the average PSA value is 87.5 ng/mL
(minimum 5.45 ng/mL, maximum 550 ng/mL). Thirteen
patients have a Gleason score of 8 or higher. At the time of
diagnosis, there were 14 patients with stage T2, 6 with stage T3,
and 4 with stage T4. There are six patients diagnosed with bone
metastasis by isotopic bone scanning; of note 2 patients with
oligometastic prostate cancer received radical resection. Four
patients were diagnosed with lymph node metastasis. Nineteen
patients received radical resection, and 3 received local
radiotherapy. Eight patients received ADT, and 2 received
ADT combined with local radiotherapy after radical resection.
By MAY 1, 2021, 5 patients showed biochemical recurrence, and
one developed into CRPC (Table 1).

Cases and Pedigrees
Among the 24 patients, the data of 4 families of HRR-related
mutation carriers are further analyzed. In these four pedigrees, 2
with germline mutation of BRCA2 (Patient A and B), 1 with
germline mutation of BRCA1, 1 with germline mutations of
BRCA2 and PALB2 (Table 2). Of note, patient B with novel
BRCA2 germline mutation responded well to chemotherapy
combined with ADT treatment in our previous report (2). In
addition, we recently reported the other patient D with BRCA2
and PALB2 mutations, who responded well to radiotherapy and
chemotherapy combined with ADT (3). For the other two
patients, Patient A was diagnosed with PCa by needle biopsy
at 52 years old, with a low PSA level of 7.95ng/dL, Gleason scores
4 + 5, imaging examination revealed no metastasis (T2bN0M0).
This patient received radical resection of the prostate, and the
PSA level closed to 0 during the follow-up. Results from Sanger
sequencing indicate that his healthy brother shares the same
germline mutation of BRCA2 (c.4211C>G, p.S1404Ter), and his
father died of bladder cancer at the age of 60. Patient C was
diagnosed with PCa at 60 years old through needle biopsy with
his PSA level of more than 550 ng/dL, Gleason scores 5 + 5,
imaging examination revealed multiple bone metastasis

Mutation Status
A total of 62 germline mutations in 45 genes were detected in 24
peripheral venous blood samples (Figure 1). Missense mutation
is the most common type, followed by stop-gained mutation and
in-frame mutation. The detection rate of a missense mutation in
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TABLE 1 | General information of all patients.
Category
Cases
Mean age of diagnosis (years old)
Family history
First degree relative
Non-ﬁrst- degree relative
Gleason score at diagnosis
≤7
≥8
Pathological type
IDC-P
TNM stage
T1/T2
T3/T4
Lymph node metastasis
N1
Bone metastasis
PSA level at diagnosis
Average value (ng/mL)
CRPC

DRGs’ mutation carriers

None carriers

P value

Total

14
54

10
55.9

0.36 (t test)

24
54.8

6
3

2
1

5
9

6
4

1

0

7
7

7
3

3
4

1
2

120
1

41.2
0

8
4
0.41 (ﬁsher exact test)

11
13
1

0.42 (ﬁsher exact test)

14
10
4
6

0.15 (ANOVA analysis)

87.5
1

DRGs, DNA repair genes; IDC-P, intraductal carcinoma of the prostate; PSA, prostate speciﬁc antigen; CRPC, castration-resistent prostate cancer.

PCa incidence and the early-onset of PCa. Dissimilarly, in the
early-onset population of our study, we found that the frequency
of PCa patients with germline mutations in DRGs was 58.3% (14/
24), much higher than that in PCa patients with undeﬁned ages
(the patients diagnosed with prostate cancer at any ages, not
restricted to the early-onset ages). Consistent with a recent report
(18), we found that patients with DRGs’ germline mutations
have higher Gleason scores, more advanced clinical stages, and
more metastasis. More importantly, compared with another PCa
cohort with undeﬁned average ages in Ye et al.’s Chinese
population (1), we found that early-onset PCa patients with
DRGs’ mutations had a relatively younger ages (54 vs 60 years)
and higher PSA levels at diagnosis (120 vs 100 ng/ml), but lower
Gleason Scores (≥8, 64.3% vs 84%) and fewer metastasis (28.6%
vs 71%). The discrepancy might be due to the limited sample size
and that most of the mutations were VUS. Thus the results
should be substantiated in a larger size of samples.
HRR pathway plays a vital role in maintaining the stability of
the genome, along with multiple repair mechanisms, including
base excision repair (BER) of DNA single-strand breaks,
mismatch repair (MMR), and non-homologous end joining
(NHEJ) (9, 10). In fact, HRR is the most efﬁcient repair tool
for DNA double-strand breaks (DSB) with high ﬁdelity, and
BRCA1/2 plays an indispensable role in this process (11, 12).
Therefore, mutations in BRCA1/2 are closely related to various
cancers, especially breast and ovarian cancer in women and PCa
in men (13–15). Previous study has shown that BRCA1/2
mutations drive carcinogenesis through somatic inactivating
the second wild-type allele, the “two-hit hypothesis”. Due to
the combination of germline and somatic mutations, the failure
of the BRCA-related HRR mechanism favour the activation of
alternative and less effective DNA repair pathways, and ﬁnally
result in tumor development (19, 20). Our previous report had
also revealed that patient D had loss-of-heterozygosity of BRCA2
in his prostate tumors (3). In addition to DNA repair pathways,

(T3NxM1B). He received ADT combined with radiotherapy.
However, his PSA reached the lowest level (0.51 ng/dL) after the
radiotherapy before raising again. This patient was diagnosed as
CRPC on Aug 28, 2020, then given abiraterone combined with
docetaxel and nedaplatin, and PSA level slowly increased to 70
ng/dL in April of 2021. The patient and his father carry the
germline mutation of BRCA1 (c.4166G>A, p.S1389N), with no
cancer history of other family members. The pedigrees of patient
A and patient C are shown in Figure 3.

DISCUSSION
In our study, we investigated the germline mutations of 24
patients with early-onset PCa by using targeted gene
sequencing of a panel of 139 genes. We found that 58.3% of
the early-onset PCa patients carried DRGs’ mutations, including
pathogenic/likely pathogenic and VUS. More importantly, we
found that in early-onset cohorts patients with DRGs’ mutations
have a tendency of higher Gleason score, higher PSA level at
diagnosis, and younger ages. At last, by analyzing the case series
and their pedigrees in details, we also found that patients with
mutations of HRR-related genes might beneﬁt from ADT
combined with radiotherapy or platinum-based chemotherapy.
PCa is one of the most heritable cancers (4), and germline
mutations in DRGs are more accountable for PCa inheritability
(5), with about 22% of PCa patients harbor DRGs’ somatic
mutations (6). As for germline mutations, DRGs’ mutations
present approximately 4.6% in localized PCa, and 11.8% to
16.2% in metastatic disease in Caucasian population (7, 8).
Whereas in Chinese population, Ye et al. have found that 9.8%
PCa patients have germline mutations in their DNA repair
pathway, and 6.3% of them are BRCA2 mutations with 0.63%
of either BRCA1 or ATM (1). Consistently, our ﬁndings in this
study show that mutations in DRGs are highly associated with
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FIGURE 1 | A waterfall plot shows the mutation ratio, mutation type of the mutated genes, and the clinical features of the 24 patients. The top panel shows the
number of the mutations in each PCa sample; the left panel shows the frequently mutated genes; the right panel shows the detection ratio of each mutated gene;
the bottom panel shows the sample number and the clinical features of the corresponding patient.

progression (16, 17). We also found that two young patients
with germline mutations have relatively low PSA levels (<4ng/
dL). Since the PSA level is not sensitive enough to screen PCa for
these kinds of patients with DRGs’ mutations, an imaging
examination should be conducted for these patients when
encountering PCa-related symptoms at a young age (25).
In addition to DRGs’ mutations, mutations in HOXB13 and
GJB2 genes have also been associated with PCa in previous studies.
HOX is a highly conserved gene encoding homeodomaincontaining transcription factors playing a vital role in body axis
patterning and cell differentiation of developing embryos (26).
Aberrations in HOX gene expression have been reported in
abnormal development and malignancy, indicating that altered
expression of HOX could be essential for both tumorigenesis and

BRCA1/2 also could repress the progression of prostate cancer by
inhibiting PI3K/AKT and MAP/ERK pathways, as well as MMP9
and AR signaling (21). It has been reported that PCa patients
with BRCA1/2 mutations can be treated with radiotherapy,
cisplatin, anthracyclines, or poly (ADP-ribose) polymerase
inhibitors (22, 23). For metastatic castration-resistant PCa with
bi-allelic inactivation of BRCA2, chemotherapy with platinum
agents has been recommended (24). In our study, the three PCa
patients carrying heterozygous BRCA2 germline mutations were
treated with ADT combined with radiotherapy or chemotherapy,
both primary lesions and metastases shrunk signiﬁcantly, and
their PSA levels were well controlled. In addition, mutations of
other HRR-related factors such as ATM, ATR, BRIP1, CDK12,
and CHEK2 also play vital roles in tumorigenesis and
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A

B

C

FIGURE 2 | Locations of the germline mutations in BRCA2 (A), BRCA1 (B) and GJB2 (C).

tumor suppression (27). Ewing et al. ﬁrstly found that a rare
germline mutation c.252G–>A (p.G84E, rs138213197) in the ﬁrst
exon of HOXB13 is associated with an increased risk of nonaggressive PCa at a young-onset (28). Soon afterward, HOXB13
mutation (c.G216C and c.R229G) was detected in PCa patients with
African and Asian ancestry as well (29). A carrier frequency of G84E
mutation among European-Americans with familial young-onset
PCa is 3.1%, but its frequency is threefold higher (8.4%) for both the
Finnish and Swedish populations (30). Although uncommon, this
mutation accounts for an eightfold increased risk of PCa diagnosed
at 55 or younger (31). This mutation is more associated with
hereditary PCa (OR: 6.6; 95% CI 3.3 to 12.0) (32). It has been
reported that in a Finnish population that HOXB13 G84E mutation
is associated with familial young-onset (<55 years) PCa with
elevated PSA (20ng/mL or higher) at the time of diagnosis. Other
than the G84E mutation in HOXB13 is mainly reported in the
Western population, a similar mutation of G135E in HOXB13
reported by LIN X et al. (33) has been associated with an increased
risk of PCa in the Chinese population. However, there is no
evidence showing that these mutations are associated with other

clinical aggressiveness, such as higher Gleason score, progression, or
recurrence. In this study, the two patients carrying the V278L
germline mutation of the HOXB13 gene were diagnosised at 50 and
55 years old, respectively. However, due to the small number of the
total subjects, there is not enough relevant evidence to reveal the
connection between mutations status and clinical features. Previous
study also revealed that HOXB13, together with FOXA1 and
GATA2, interacts with androgen receptor (AR) to promote the
development and differentiation of prostate and PCa (34), while the
exact mechanism of HOXB13 in carcinogenesis remains unclear.
GJB2 encodes a gap junction protein and is a putative tumor
suppressor. However, more recent studies also showed that the
expression level of GJB2 in metastatic tumor lesions is signiﬁcantly
higher than that in the primary tumor, suggesting that GJB2 may
promote tumor metastasis (35). Mutations in GJB2 gene are usually
associated with non-syndromic hearing loss (NSHL) (36). It has
been reported that a 17.3% biallelic mutation of the GJB2 gene in the
Chinese population (37). Since GJB2 and its isoforms express at
different levels in PCa tissues, it is suggested that GJB2 may play a
role in PCa tumorigenesis (38, 39). Our ﬁndings show that the rate

TABLE 2 | Mutations status of the four patients with pedigrees.
Patient

A
B
C
D

Gene

Type of mutation

Nucleotide changes

Amino acid changes

Chromosomes

Exon

Transcript

BRCA2
BRCA2
BRCA1
BRCA2
PALB2

Stop-gain
Stop-gain
Missense mutation
Frameshift
Frameshift

c.1799_1804del
c.4211C>G
c.4166G>A
c.8474_8487delCATACCCTATACAG
c.472delC

p.Tyr600_Gly602delinsTer
p.S1404Ter
p.S1389N
p.A2825Vfs*15
p.Q158Rfs*19

13
13
17
13
16

10/27
16/27
12/22
19/27
4/13

NM_000059.3
NM_000059.3
NM_007294.3
NM_000059.3
NM_024675.3

Homozygous/
heterozygous
heterozygous
heterozygous
heterozygous
heterozygous
heterozygous

The symbol * means termination codon.

Frontiers in Oncology | www.frontiersin.org

6

June 2022 | Volume 12 | Article 826778

Tang et al.

Germline Mutations in Early-Onset PCa

A

B

FIGURE 3 | Family pedigrees of Patient A (A) and Patient C (B), respectively. “□,○” indicate normal males and females, red “\” indicates that individual is deceased,
dashes between symbols “□—○” indicate a couple, “?” indicate the mutation status is unknown, and “↘” indicate the probands. PCa represents prostate cancer.

have advanced stages of tumors at diagnosis (46). At last, there
are only a few patients with prostate cancer aged ≤55 years,
who fulﬁlled all the inclusion criteria. Therefore, we used the
age under 65 years old as early-onset in our cohort. Of note,
half of the patients were diagnosed as prostate cancer at ages ≤
55 years, only two patients were diagnosed at ages over 60
years old. Another limitation is that most of the mutations in
our report are VUS. The effects of the mutations need to be
further revealed.

of germline GJB2 mutation in PCa patients is 20.8% (5/24), higher
than the rate in the general populations, indicating that GJB2
mutations might be associated with early-onset PCa. However,
the role of GJB2 on PCa need to be further substantiated and the
underlying mechanism remains to be unclear.
The major limitation of the present study is the small
sample size, which might due to the speciﬁc particular cohort,
early-onset prostate cancer. We have deﬁned patients at ages
under 65 years old as early-onset ones in our cohort according
to previous studies (40–43). We noted that the current
deﬁnition of early-onset prostate cancer is indeed not the
classical or common used one (aged ≤55 years) according to
previous report (44). However, we have a few reasons to use
the current deﬁnition in our cohort. Firstly, previous study has
shown that the mean age of prostate cancer patients in Asian
population are higher than those in Caucasian population,
suggesting a delay in prostate cancer development in Asian
men (45). Secondly, the tumour latency period, the time when
the tumour exists but is not detected (starts at tumour onset
and ends at diagnosis by screening or clinical symptoms),
might be longer in China; which might be due to the lack of
routine PSA screening to certain extent. Thus most of the
patients were not admitted to hospital until signiﬁcant clinical
symptoms appeared, evidenced by that most of the patients
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CONCLUSIONS
The incidence of early-onset prostate cancer increased since PSA
screening was introduced. The biological differences exist between
early-onset prostate cancer and late-onset disease. In our study, we
found that germline mutation in DRGs is one of the major risk factors
for early-onset and a more aggressive PCa. Since the PSA level in
early-onset PCa with DRGs’ mutations could be relatively normal,
more aggressive imaging examination is suggested than PSA
screening for these kinds of patients. HRR-related mutation
carriers might beneﬁt from ADT combined with chemo/
radiotherapy. Therefore, genetic testing is rather important to guide
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precise therapy for the patients with early-onset PCa and to direct
their family members to clinical genetic counseling.

XW, and JJ. Manuscript writing and revising: TT, XT, QL, DZ,
and JJ. All authors contributed to the article and approved the
submitted version.
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